Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

Cancer Gene Therapy

Volumn 12, Issue 6, 2005, Pages 540-551

  Medin, Jeffrey A ^a,b,e   Liang, Sheng Ben ^a   Hou, Jeannie Whit Shan ^c   Kelley, Leslie S ^d   Peace, David J ^d   Fowler, Daniel H ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Dendritic cells; Immunotherapy; Onco retrovirus

Indexed keywords

BASILIXIMAB; CD8 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROTECTION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; SENSITIZATION; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DNA, COMPLEMENTARY; FEMALE; GENE THERAPY; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-2;

MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 18844416079     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700810     Document Type: Article

References (40)

1. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30A:1797-1803.
2. Wei C, Storozynsky E, McAdam AJ, et al. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1996;42:362-368.
3. Liu KJ, Chatta GS, Twardzik DR, et al. Identification of rat prostatic steroid-binding protein as a target antigen of experimental auto-immune prostatitis: implications for prostate cancer therapy. J Immunol. 1997;159:472-480.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
5. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol. 1991;9:271-296.
6. Aalamian M, Pirtskhalaishvili G, Nunez A, et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 2001;46: 68-75.
7. L increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol. 2000;165: 1956-1964.
8. Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol. 1998;160:214-219.
9. Takenaka T, Murray GJ, Qin G, et al. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA. 2000;97:7515-7520.
10. Qin G, Takenaka T, Telsh K, et al. Pre-selective gene therapy for Fabry disease. Proc Natl Acad Sci USA. 2001;98:3428-3433.
11. Henderson RA, Nimgoankar MT, Watkins SC, et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 1996;56:3763-3770.
12. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56:5672-5677.
13. Song ES, Lee V, Surh CD, et al. Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1997;94:1943-1948.
14. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med. 1997;186:1213-1221.
15. Parajuli P, Mosley RL, Pisarev V, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T cell subsets. Exp Hematol. 2001;29:1185-1193.
16. Ward AM, Catto JWF, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem. 2001;38:633-651.
17. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate. 1997;30:73-78.
18. Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogens. 1998;17:3125-3135.
19. Heiser A, Maurice MA, Yancey DR, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953-2960.
20. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: current and future utility. Sem Urol Oncol. 1998;16:2-12.
21. Tasch J, Gong M, Sadelain M, Heston WDW. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol. 2001;21:249-261.
22. Kim J, Palmer, JL, Finn L, et al. The pattern of serum markers in androgen-independent adenocarcinoma of the prostate. Urologic Oncol. 2000;5:97-103.
23. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192-3198.
24. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000;38:208-217.
25. Henttu P, Vihko P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun. 1989;160:903-910.
26. Takenaka T, Qin G, Brady RO, Medin JA. Circulating α-galactosidase A derived from transduced bone marrow cells: relevance to gene therapy for Fabry disease. Hum Gene Ther. 1999;10:1931-1939.
27. Gehring U, Mohit B, Tomkins GM. Glucocorticoid action on hybrid clones derived from cultured myeloma and lymphoma cell lines. Proc Natl Acad Sci USA. 1972;69: 3124-3127.
28. Foster BA, Gingrich JR, Kwon ED, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarconoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57:3325-3330.
29. Garlie NK, Lefever AV, Siebenlist RE, et al. T cells co-activated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother. 1999;22:336-345.
30. Olsson AY, Lundwall A. Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem Biophys Res Comm. 2002;299:305-311.
31. Lapointe R, Royal RE, Reeves ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC Class I and Class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001;167:4758-4764.
32. Fan L, Owen JS, and Dickson, G. Construction and characterization of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase. Atherosclerosis. 1999;147:139-145.
33. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
34. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
35. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999;40:125-129.
36. Huang YM, Yang JS, Xu LY, et al. Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000;122:437-444.
37. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165: 3797-3803.
38. Medin JA, Karlsson S. Viral vectors for gene therapy of hematopoietic cells. Immunotech. 1997;3:3-19.
39. + dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 2000;7:249-254.
40. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood. 2001;97:114-121.